CNS Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive cancers of the brain and central nervous system. Its current work centers on advancing anti-cancer drug candidates designed to address high-unmet-need diseases such as glioblastoma and other malignant brain tumors. The company’s pipeline includes investigational compounds such as berubicin and other neurology and oncology assets, reflecting its emphasis on treatments that can reach and act within the central nervous system. CNS Pharmaceuticals Inc. operates in the specialized oncology segment of the pharmaceutical market, where drug development is shaped by the challenges of treating tumors protected by the blood-brain barrier. The company is based in Houston, Texas, and its role in the market is to develop novel hospital- and specialist-directed treatment options for severe brain and CNS cancers.
Website2100 West Loop South
Houston, TX, 77027
United States
Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" SegmentAccess the segment hereHOUSTON, TX / ACCESS Newswire / September 1, 2026 / (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment.Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provided an update on
Video webcast now available hereHOUSTON, TX / ACCESS Newswire / August 27, 2026 / (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference.Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's strategic transformation that is being built on the strength of
Company reports approximately $20.0 million cash position and extended operating runway following oversubscribed $22.5 million financing, as it advances its pivot toward a diversified, high-value pipeline HOUSTON, TX / ACCESS Newswire / August 12, ...
Investors talking about CNSP also mention
What share of all stock conversation is about CNSP?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0% 0 | 0% 0 | 0% 0 | 0% -0.01 |
Of the messages about CNSP that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | — | — | 91.15% +4.82 | ||
| Bearish | — | — | — | 8.85% -4.82 |
Of the messages about CNSP that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | — | — | — | 52.02% | ||
| Analysts | — | — | — | 4.36% | ||
| Controversies | — | — | — | 0.16% | ||
| Earnings | — | — | — | 0.16% | ||
| Macro | — | — | — | 2.42% | ||
| Technical Analysis | — | — | — | 40.87% |
Of the messages about CNSP, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | — | — | 0% | 36.18% | ||
| Newcomers | — | — | 100% | 63.82% |